Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06750276 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT06750276 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 40 participants.
The verdict
NCT06750276, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body
Interventions
- DRUG AZD2389
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2025-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06750276
The ClinicalTrials.gov registry entry for NCT06750276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD2389 is the first listed.
NCT06750276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06750276 about?
NCT06750276 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.". The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body
What is the current status of trial NCT06750276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-12-06. Estimated completion is 2025-07-28.
What interventions are being tested in trial NCT06750276?
The interventions under investigation include: AZD2389 (DRUG).
Who is sponsoring clinical trial NCT06750276?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.